Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic effect of coenzyme Q10 on contrast-induced nephropathy in type 2 diabetes mellitus
IRCT20120215009014N337Phase 2Completed
- Sponsor
- Hamadan University of Medical Sciences
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in contrast-induced nephropathy (CIN), type 2 diabetes mellitus (T2DM) and diabetic glomerulosclerosis comparing Coenzyme Q10 prophylaxis with Placebo (2 arms). Primary endpoint: Incidence of contrast-induced nephropathy. Started Feb 2020; status: completed.
02
Drugs
coenzyme q10
03
Conditions
contrast-induced nephropathy (CIN)type 2 diabetes mellitus (T2DM)diabetic glomerulosclerosis
Beyond the preview
Go deeper on IRCT20120215009014N337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20120215009014N337.